Kenneth L. Londoner, MBA
Founder, Chief Executive Officer, Chairman and Director
Mr. Londoner founded BioSig Technologies, Inc. in February 2009. Mr. Londoner is the Managing Partner of Endicott Management Partners, LLC, a firm dedicated to assisting emerging growth companies in their corporate development and investing needs since 2004. From April 2007 to October 2009, Mr. Londoner was the executive vice president of NewCardio, Inc., a silicon valley based cardiac software company. Mr. Londoner also served as a Director and the architect for the turnaround at Alliqua BioMedical, Inc. (Nasdaq: ALQA) from May 2012 to March 2014. Mr. Londoner is a co-founder of Safe Ports Holdings, LLC, in Charleston, South Carolina, a port security and logistics company. Started in July 2005, the company built and sold an inland port development project to Dubai Ports World. The sale, in the fall of 2007, was for almost six times what investors had invested. Mr. Londoner is a member of Safe Ports Board of Directors. Mr. Londoner was the founder and managing partner of Red Coat Capital Management in New York. Founded in late 1996, the hedge fund (long/short equity strategy) grew from its initial base of $ 2 million in assets to a peak of $ 1.1 billion. Mr. Londoner started his investment career at J. & W. Seligman & Co., Inc., a leading institutional money management firm where he rose from research analyst to managing $3.5 billion in mutual funds, pension funds, and international assets. He joined Seligman in 1991 and left in 1997. Mr. Londoner graduated from Lafayette College in 1989 with a degree in economics and finance and received his MBA from NYU's Stern School of Business in 1994, with a dual major in finance and management. Mr. Londoner just celebrated his 25th wedding anniversary and has four children. Mr. Londoner has been working with Lafayette College to develop and expand a summer internship program designed to provide undergraduate students with high value summer employment in leading growth industries in the U.S.
Chief Financial Officer
Mr. Chaussy has served as our chief financial officer on a full time basis since January 2018. Mr. Chaussy served as our chief financial officer on a part time basis from May 2011 to January 2018. Since 2005, Mr. Chaussy has been the sole proprietor of Anna & Co., Inc., a consulting company that offers services to small publicly traded companies. Anna & Co., Inc. provides general financial and accounting services, with a special emphasis towards SEC reporting and compliance, to companies that lack sufficient resources to hire full-time employees to provide such services. From 2001 to 2005, Mr. Chaussy provided services as both a chief financial officer and as a consultant to small publicly traded companies. Prior to 2001, Mr. Chaussy served as chief financial officer for a large private distribution and wholesaling company, where he gained international experience. Mr. Chaussy is a graduate of Virginia Polytechnic Institute and State University and is a licensed certified public accountant in Virginia, California and Florida.
Vice President, Business Development and Corporate Finance
Natasha Russkina is a well-established finance professional. She is the founder and director of Augeous Consulting in Geneva, Switzerland, a firm that provides various levels of business development capabilities to companies in the life science sector. Ms. Russkina has over 13 years of experience in international business development, including over 9 years at IG Group PLC, a British FTSE 250 company and a global leader in online trading. During this time, she was responsible for the Group’s global business development successfully delivering a number of high level projects from opening new international branches to global rebranding, and providing all initial and ongoing business support to 12 international offices in Europe, South Africa and Australia, a business sector, which accounted for 40% of the Group’s revenue. During her career, she had been appointed by the Board of Directors to open a new IT development office in Eastern Europe and was responsible for all parts of operations. During this assignment, the office grew from 14 inherited members of staff to over 135.
Vice President, Administration
Ms. Mikolaitis helped co-found BioSig Technologies, Inc. in February 2009. As Vice President of Administration, her role encompasses a wide range of duties that began with co-writing the business plan to now co-writing marketing materials and SEC filings. She supports many of the departments of the Company including shareholder/investor/public relations, accounting/finance, legal, marketing, human resources, and research and development. Ms. Mikolaitis is also President of Miko Consulting Group, Inc., a firm that provides marketing research and administrative support to life science companies.
Joseph W. Rafferty
Chief Commercialization Officer
Mr. Rafferty brings to BioSig over 30 years of leadership experience with traditional corporate and emerging growth companies. Having functioned as CEO, GM, VP Global Sales-Marketing, VP Physician Training, VP Sales Training and Director for National Contracts, Mr. Rafferty has created a legacy of building and leading highly successful teams with industry leaders like Pathway Medical, Avinger, ACS/Guidant, CR Bard Vascular/Cardiovascular, Synthes Spine, Sterilox, J&J's Ethicon Mechanical Products (Endo) and, most recently, as CEO of National Medical Sales, LLC.
Chief Regulatory and Compliance Officer
Mrs. Wittwer brings to BioSig over 15 years of experience in FDA regulatory affairs on behalf of public and private companies, most notably Trice Medical, Inc., Embrella Cardiovascular, Inc. (acquired by Edwards Lifesciences in 2011) and Cardica, Inc. During her career, Mrs. Wittwer has successfully delivered FDA 510(k) clearance of mi-eye(TM) and mi-eye 2(TM) visualization systems for Trice Medical and CE mark for Embrella Cardiovascular’s Embolic Deflector system for the use during transcatheter heart valve procedures. In 2016, the sales of transcatheter heart valves represented 55% of all net sales of Edwards Lifesciences.